25 XP   0   0   10

aTyr Pharma Inc
Buy, Hold or Sell?

Let's analyse aTyr Pharma Inc together

PenkeI guess you are interested in aTyr Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of aTyr Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about aTyr Pharma Inc

I send you an email if I find something interesting about aTyr Pharma Inc.

Quick analysis of aTyr Pharma Inc (30 sec.)










What can you expect buying and holding a share of aTyr Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.04
When do you have the money?
1 year
How often do you get paid?
17.5%

What is your share worth?

Current worth
$1.34
Expected worth in 1 year
$1.62
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$0.33
Return On Investment
20.3%

For what price can you sell your share?

Current Price per Share
$1.62
Expected price per share
$1.48 - $2.1162
How sure are you?
50%

1. Valuation of aTyr Pharma Inc (5 min.)




Live pricePrice per Share (EOD)

$1.62

Intrinsic Value Per Share

$-33.71 - $-9.02

Total Value Per Share

$-32.37 - $-7.68

2. Growth of aTyr Pharma Inc (5 min.)




Is aTyr Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$90.4m$83.2m$17.8m17.6%

How much money is aTyr Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$12.3m-$11m-$1.3m-10.6%
Net Profit Margin-803.1%-17.1%--

How much money comes from the company's main activities?

3. Financial Health of aTyr Pharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#387 / 1010

Most Revenue
#636 / 1010

Most Profit
#593 / 1010

Most Efficient
#783 / 1010

What can you expect buying and holding a share of aTyr Pharma Inc? (5 min.)

Welcome investor! aTyr Pharma Inc's management wants to use your money to grow the business. In return you get a share of aTyr Pharma Inc.

What can you expect buying and holding a share of aTyr Pharma Inc?

First you should know what it really means to hold a share of aTyr Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of aTyr Pharma Inc is $1.62. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of aTyr Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in aTyr Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.34. Based on the TTM, the Book Value Change Per Share is $0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of aTyr Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.22-13.4%-0.19-11.6%-0.17-10.3%-0.13-7.7%-0.16-9.9%
Usd Book Value Change Per Share-0.11-7.0%0.074.4%-0.14-8.6%0.042.6%0.031.7%
Usd Dividend Per Share0.000.0%0.010.7%0.000.0%0.010.4%0.000.2%
Usd Total Gains Per Share-0.11-7.0%0.085.1%-0.14-8.6%0.053.0%0.031.9%
Usd Price Per Share1.41-1.81-3.34-3.47-3.51-
Price to Earnings Ratio-1.62--2.46--5.02--5.72--4.56-
Price-to-Total Gains Ratio-12.35--23.86--24.32--63.95--44.33-
Price to Book Ratio1.06-1.21-2.66-4.60-3.70-
Price-to-Total Gains Ratio-12.35--23.86--24.32--63.95--44.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.62
Number of shares617
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.070.04
Usd Total Gains Per Share0.080.05
Gains per Quarter (617 shares)50.6129.51
Gains per Year (617 shares)202.44118.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12817519215103108
25534939429207226
38352459644310344
411169979858414462
5139874100073517580
61661048120287621698
719412231404102724816
822213981606116828934
9249157318081319311052
102771747201014510351170

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%3.037.00.07.5%19.037.00.033.9%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%8.030.02.020.0%18.036.02.032.1%
Dividend per Share2.00.02.050.0%3.00.09.025.0%6.00.014.030.0%7.00.033.017.5%8.00.048.014.3%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%8.030.02.020.0%18.036.02.032.1%

Fundamentals of aTyr Pharma Inc

About aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-11 13:21:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of aTyr Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit aTyr Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare aTyr Pharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of aTyr Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-803.1%+803.1%
TTM-803.1%YOY-17.1%-786.0%
TTM-803.1%5Y-4,014,104.0%+4,013,300.9%
5Y-4,014,104.0%10Y-2,007,052.0%-2,007,052.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM-803.1%-216.8%-586.3%
YOY-17.1%-288.3%+271.2%
5Y-4,014,104.0%-449.1%-4,013,654.9%
10Y-2,007,052.0%-605.5%-2,006,446.5%
1.1.2. Return on Assets

Shows how efficient aTyr Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare aTyr Pharma Inc to the Biotechnology industry mean.
  • -12.1% Return on Assets means that aTyr Pharma Inc generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of aTyr Pharma Inc:

  • The MRQ is -12.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.1%TTM-9.6%-2.4%
TTM-9.6%YOY-11.3%+1.6%
TTM-9.6%5Y-11.2%+1.6%
5Y-11.2%10Y-13.0%+1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.1%-13.3%+1.2%
TTM-9.6%-12.8%+3.2%
YOY-11.3%-11.7%+0.4%
5Y-11.2%-13.9%+2.7%
10Y-13.0%-15.7%+2.7%
1.1.3. Return on Equity

Shows how efficient aTyr Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare aTyr Pharma Inc to the Biotechnology industry mean.
  • -16.3% Return on Equity means aTyr Pharma Inc generated $-0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of aTyr Pharma Inc:

  • The MRQ is -16.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -12.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.3%TTM-12.4%-3.9%
TTM-12.4%YOY-13.3%+0.9%
TTM-12.4%5Y-14.8%+2.4%
5Y-14.8%10Y-19.2%+4.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.3%-16.9%+0.6%
TTM-12.4%-16.1%+3.7%
YOY-13.3%-15.1%+1.8%
5Y-14.8%-19.3%+4.5%
10Y-19.2%-20.2%+1.0%

1.2. Operating Efficiency of aTyr Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient aTyr Pharma Inc is operating .

  • Measures how much profit aTyr Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare aTyr Pharma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of aTyr Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-963.7%+963.7%
TTM-963.7%YOY-20.8%-942.9%
TTM-963.7%5Y-4,201,394.3%+4,200,430.5%
5Y-4,201,394.3%10Y-2,100,697.1%-2,100,697.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-963.7%-232.5%-731.2%
YOY-20.8%-298.2%+277.4%
5Y-4,201,394.3%-492.1%-4,200,902.2%
10Y-2,100,697.1%-632.4%-2,100,064.7%
1.2.2. Operating Ratio

Measures how efficient aTyr Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of aTyr Pharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM9.887-9.887
TTM9.887YOY0.458+9.429
TTM9.8875Y40,519.426-40,509.539
5Y40,519.42610Y20,259.713+20,259.713
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM9.8873.310+6.577
YOY0.4583.890-3.432
5Y40,519.4265.739+40,513.687
10Y20,259.7137.876+20,251.837

1.3. Liquidity of aTyr Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if aTyr Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.27 means the company has $6.27 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of aTyr Pharma Inc:

  • The MRQ is 6.274. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.158. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.274TTM8.158-1.884
TTM8.158YOY10.036-1.877
TTM8.1585Y8.235-0.077
5Y8.23510Y7.230+1.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2743.890+2.384
TTM8.1584.173+3.985
YOY10.0365.344+4.692
5Y8.2356.126+2.109
10Y7.2306.448+0.782
1.3.2. Quick Ratio

Measures if aTyr Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare aTyr Pharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 10.73 means the company can pay off $10.73 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of aTyr Pharma Inc:

  • The MRQ is 10.735. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 14.572. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.735TTM14.572-3.837
TTM14.572YOY17.704-3.132
TTM14.5725Y13.760+0.812
5Y13.76010Y11.403+2.357
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.7353.514+7.221
TTM14.5723.998+10.574
YOY17.7045.380+12.324
5Y13.7606.105+7.655
10Y11.4036.404+4.999

1.4. Solvency of aTyr Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of aTyr Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare aTyr Pharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.26 means that aTyr Pharma Inc assets are financed with 25.9% credit (debt) and the remaining percentage (100% - 25.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of aTyr Pharma Inc:

  • The MRQ is 0.259. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.218. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.259TTM0.218+0.041
TTM0.218YOY0.154+0.065
TTM0.2185Y0.218+0.001
5Y0.21810Y0.302-0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2590.339-0.080
TTM0.2180.336-0.118
YOY0.1540.271-0.117
5Y0.2180.366-0.148
10Y0.3020.389-0.087
1.4.2. Debt to Equity Ratio

Measures if aTyr Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare aTyr Pharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 34.9% means that company has $0.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of aTyr Pharma Inc:

  • The MRQ is 0.349. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.280. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.349TTM0.280+0.068
TTM0.280YOY0.192+0.089
TTM0.2805Y0.306-0.026
5Y0.30610Y0.388-0.081
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3490.388-0.039
TTM0.2800.402-0.122
YOY0.1920.335-0.143
5Y0.3060.426-0.120
10Y0.3880.461-0.073

2. Market Valuation of aTyr Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings aTyr Pharma Inc generates.

  • Above 15 is considered overpriced but always compare aTyr Pharma Inc to the Biotechnology industry mean.
  • A PE ratio of -1.62 means the investor is paying $-1.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of aTyr Pharma Inc:

  • The EOD is -1.859. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.618. Based on the earnings, the company is expensive. -2
  • The TTM is -2.457. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.859MRQ-1.618-0.241
MRQ-1.618TTM-2.457+0.838
TTM-2.457YOY-5.021+2.565
TTM-2.4575Y-5.719+3.262
5Y-5.71910Y-4.560-1.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.859-2.264+0.405
MRQ-1.618-2.629+1.011
TTM-2.457-2.680+0.223
YOY-5.021-4.145-0.876
5Y-5.719-6.257+0.538
10Y-4.560-6.254+1.694
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of aTyr Pharma Inc:

  • The EOD is -2.477. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.156. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.678. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.477MRQ-2.156-0.321
MRQ-2.156TTM-6.678+4.523
TTM-6.678YOY-5.343-1.335
TTM-6.6785Y-7.005+0.327
5Y-7.00510Y-6.304-0.701
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.477-2.973+0.496
MRQ-2.156-3.333+1.177
TTM-6.678-3.553-3.125
YOY-5.343-5.605+0.262
5Y-7.005-8.376+1.371
10Y-6.304-8.865+2.561
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of aTyr Pharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.06 means the investor is paying $1.06 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of aTyr Pharma Inc:

  • The EOD is 1.213. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.056. Based on the equity, the company is underpriced. +1
  • The TTM is 1.206. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.213MRQ1.056+0.157
MRQ1.056TTM1.206-0.150
TTM1.206YOY2.656-1.450
TTM1.2065Y4.599-3.393
5Y4.59910Y3.703+0.896
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.2131.896-0.683
MRQ1.0562.115-1.059
TTM1.2062.093-0.887
YOY2.6562.884-0.228
5Y4.5993.542+1.057
10Y3.7033.916-0.213
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of aTyr Pharma Inc.

3.1. Institutions holding aTyr Pharma Inc

Institutions are holding 61.916% of the shares of aTyr Pharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Federated Hermes Inc17.36610.03561016960000
2023-12-31FMR Inc150.00187840092270842.6538
2023-12-31Logos Global Management LP9.98970.77585000058500000
2023-12-31Tikvah Management LLC4.20221.1908246083300
2023-09-30Alyeska Investment Group, L.P.4.19320.0264245555525000011.335
2023-12-31Vanguard Group Inc4.04450.00012368454848483.7155
2023-09-30Citadel Advisors Llc3.04670.000617841361464046457.3857
2023-12-31Checkpoint Capital LP2.56751.2841150355415035540
2023-12-31BlackRock Inc2.32640.0001136236048570.3578
2023-12-31Renaissance Technologies Corp1.49930.001987797237197973.5147
2023-12-31Geode Capital Management, LLC1.00240.000158699700
2023-12-31Stonepine Capital Management Llc0.82350.2941482258-4144366-89.5765
2023-09-30TANG CAPITAL MANAGEMENT LLC0.80450.105471134321134214.0893
2023-12-31Pale Fire Capital SE0.50150.0647293706237849425.8177
2023-12-31Goldman Sachs Group Inc0.490302871402871400
2023-12-31State Street Corporation0.2848016680800
2023-12-31Bank of America Corp0.2540148759148643128140.5172
2023-12-31Two Sigma Advisers, LLC0.25230.0005147750-41500-21.9287
2023-12-31Dimensional Fund Advisors, Inc.0.24290.0001142248-94201-39.8399
2023-12-31Millennium Management LLC0.21380.00011252264091248.5234
Total 69.10563.775240468499+6511979+16.1%

3.2. Funds holding aTyr Pharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Federated Hermes Kaufmann Small Cap Grow7.76970.1765526400000
2023-12-31Federated Hermes Kaufmann Small Cap A7.76970.1765526400000
2023-12-31Federated Hermes Kaufmann Growth7.06270.1384478500000
2023-12-31Federated Hermes Kaufmann R7.06270.1383478500000
2024-02-29Fidelity Growth Compy Commingled Pl O4.46660.0074302615500
2024-02-29Fidelity Select Biotechnology3.33290.0882225806300
2024-02-29Fidelity Growth Company Fund3.0810.0067208740100
2024-02-29Vanguard Total Stock Mkt Idx Inv2.43960.0002165283500
2024-02-29Fidelity Growth Company K61.2140.008682250300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.97740.001366220600
2024-02-29Fidelity Series Growth Company0.87070.007258988700
2024-02-29Fidelity Extended Market Index0.42740.0015289546-1403-0.4822
2024-02-29Fidelity Total Market Index0.26990.000418286900
2023-09-30BlackRock Extended Mkt Composite0.2380.001816126800
2024-03-31BlackRock Extended Equity Market K0.20770.0019140744510.0362
2024-03-28iShares Micro-Cap ETF0.18550.026712570700
2023-12-31Federated Hermes Kaufmann II P0.1780.137612060000
2024-02-29Fidelity Series Total Market Index0.09730.00026590500
2024-03-29Avantis US Small Cap Equity ETF0.07710.01015226700
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.07370.0011499192158376.1681
Total 47.80160.930632385875+20231+0.1%

3.3. Insider Transactions

Insiders are holding 2.296% of the shares of aTyr Pharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-11Sanjay ShuklaBUY30001.17
2023-05-10Paul SchimmelBUY2000002.25

4. Summary

4.1. Key Performance Indicators

The key performance indicators of aTyr Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1140.071-261%-0.140+22%0.042-372%0.028-514%
Book Value Per Share--1.3351.492-11%1.229+9%0.962+39%0.885+51%
Current Ratio--6.2748.158-23%10.036-37%8.235-24%7.230-13%
Debt To Asset Ratio--0.2590.218+19%0.154+68%0.218+19%0.302-14%
Debt To Equity Ratio--0.3490.280+24%0.192+82%0.306+14%0.388-10%
Dividend Per Share---0.011-100%0.000-100%0.006-100%0.003-100%
Eps---0.218-0.187-14%-0.167-23%-0.125-43%-0.160-27%
Free Cash Flow Per Share---0.164-0.138-16%-0.161-2%-0.111-32%-0.125-23%
Free Cash Flow To Equity Per Share---0.0740.106-170%-0.141+89%0.036-304%0.023-417%
Gross Profit Margin--1.0281.007+2%1.000+3%1.001+3%1.001+3%
Intrinsic Value_10Y_max---9.017--------
Intrinsic Value_10Y_min---33.706--------
Intrinsic Value_1Y_max---0.560--------
Intrinsic Value_1Y_min---1.047--------
Intrinsic Value_3Y_max---1.944--------
Intrinsic Value_3Y_min---5.183--------
Intrinsic Value_5Y_max---3.644--------
Intrinsic Value_5Y_min---11.520--------
Market Cap109755000.000+13%95527500.000122796875.000-22%226454375.000-58%235216143.750-59%237827398.125-60%
Net Profit Margin----8.0310%-0.1710%-40141.0400%-20070.5200%
Operating Margin----9.6370%-0.2080%-42013.9430%-21006.9710%
Operating Ratio---9.887-100%0.458-100%40519.426-100%20259.713-100%
Pb Ratio1.213+13%1.0561.206-12%2.656-60%4.599-77%3.703-71%
Pe Ratio-1.859-15%-1.618-2.457+52%-5.021+210%-5.719+253%-4.560+182%
Price Per Share1.620+13%1.4101.813-22%3.343-58%3.472-59%3.510-60%
Price To Free Cash Flow Ratio-2.477-15%-2.156-6.678+210%-5.343+148%-7.005+225%-6.304+192%
Price To Total Gains Ratio-14.193-15%-12.353-23.858+93%-24.322+97%-63.955+418%-44.327+259%
Quick Ratio--10.73514.572-26%17.704-39%13.760-22%11.403-6%
Return On Assets---0.121-0.096-20%-0.113-7%-0.112-7%-0.130+8%
Return On Equity---0.163-0.124-24%-0.133-18%-0.148-9%-0.192+18%
Total Gains Per Share---0.1140.082-239%-0.140+22%0.048-339%0.031-474%
Usd Book Value--90470000.000101105750.000-11%83280500.000+9%65165350.000+39%59964925.000+51%
Usd Book Value Change Per Share---0.1140.071-261%-0.140+22%0.042-372%0.028-514%
Usd Book Value Per Share--1.3351.492-11%1.229+9%0.962+39%0.885+51%
Usd Dividend Per Share---0.011-100%0.000-100%0.006-100%0.003-100%
Usd Eps---0.218-0.187-14%-0.167-23%-0.125-43%-0.160-27%
Usd Free Cash Flow---11079000.000-9359000.000-16%-10881750.000-2%-7491250.000-32%-8478825.000-23%
Usd Free Cash Flow Per Share---0.164-0.138-16%-0.161-2%-0.111-32%-0.125-23%
Usd Free Cash Flow To Equity Per Share---0.0740.106-170%-0.141+89%0.036-304%0.023-417%
Usd Market Cap109755000.000+13%95527500.000122796875.000-22%226454375.000-58%235216143.750-59%237827398.125-60%
Usd Price Per Share1.620+13%1.4101.813-22%3.343-58%3.472-59%3.510-60%
Usd Profit---14760000.000-12388500.000-16%-11069250.000-25%-8371300.000-43%-9508150.000-36%
Usd Revenue---88250.000-100%2596500.000-100%1081074.338-100%540537.169-100%
Usd Total Gains Per Share---0.1140.082-239%-0.140+22%0.048-339%0.031-474%
 EOD+5 -3MRQTTM+5 -29YOY+14 -205Y+8 -2610Y+12 -22

4.2. Fundamental Score

Let's check the fundamental score of aTyr Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.859
Price to Book Ratio (EOD)Between0-11.213
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than110.735
Current Ratio (MRQ)Greater than16.274
Debt to Asset Ratio (MRQ)Less than10.259
Debt to Equity Ratio (MRQ)Less than10.349
Return on Equity (MRQ)Greater than0.15-0.163
Return on Assets (MRQ)Greater than0.05-0.121
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of aTyr Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.259
Ma 20Greater thanMa 501.770
Ma 50Greater thanMa 1001.824
Ma 100Greater thanMa 2001.643
OpenGreater thanClose1.680
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets122,067
Total Liabilities31,597
Total Stockholder Equity90,658
 As reported
Total Liabilities 31,597
Total Stockholder Equity+ 90,658
Total Assets = 122,067

Assets

Total Assets122,067
Total Current Assets102,992
Long-term Assets19,075
Total Current Assets
Cash And Cash Equivalents 22,544
Short-term Investments 75,622
Net Receivables 2,436
Other Current Assets 2,390
Total Current Assets  (as reported)102,992
Total Current Assets  (calculated)102,992
+/-0
Long-term Assets
Property Plant Equipment 14,046
Long-term Assets Other 131
Long-term Assets  (as reported)19,075
Long-term Assets  (calculated)14,177
+/- 4,898

Liabilities & Shareholders' Equity

Total Current Liabilities16,416
Long-term Liabilities15,181
Total Stockholder Equity90,658
Total Current Liabilities
Short-term Debt 1,328
Accounts payable 3,529
Other Current Liabilities 11,559
Total Current Liabilities  (as reported)16,416
Total Current Liabilities  (calculated)16,416
+/-0
Long-term Liabilities
Capital Lease Obligations 15,095
Long-term Liabilities  (as reported)15,181
Long-term Liabilities  (calculated)15,095
+/- 86
Total Stockholder Equity
Common Stock63
Retained Earnings -468,023
Accumulated Other Comprehensive Income -74
Other Stockholders Equity 558,692
Total Stockholder Equity (as reported)90,658
Total Stockholder Equity (calculated)90,658
+/-0
Other
Capital Stock63
Cash and Short Term Investments 98,166
Common Stock Shares Outstanding 59,261
Liabilities and Stockholders Equity 122,067
Net Debt -7,449
Net Invested Capital 90,658
Net Working Capital 86,576
Property Plant and Equipment Gross 18,667
Short Long Term Debt Total 15,095



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
> Total Assets 
8,455,521
8,638,997
8,507,116
9,486,199
9,275,797
9,124,623
9,046,493
9,187,963
8,579,164
8,482,010
8,558,035
8,638,065
8,539,048
8,483,747
8,488,236
39,786
0
0
0
20,644
59,905
153,081
141,369
129,675
115,125
100,486
85,925
80,524
65,735
61,472
94,487
89,355
78,470
68,308
59,774
52,746
49,915
48,762
43,745
36,188
54,447
47,562
41,636
38,726
55,128
48,995
123,916
115,537
104,776
96,016
96,055
95,786
136,838
132,747
125,069
122,067
122,067125,069132,747136,83895,78696,05596,016104,776115,537123,91648,99555,12838,72641,63647,56254,44736,18843,74548,76249,91552,74659,77468,30878,47089,35594,48761,47265,73580,52485,925100,486115,125129,675141,369153,08159,90520,64400039,7868,488,2368,483,7478,539,0488,638,0658,558,0358,482,0108,579,1649,187,9639,046,4939,124,6239,275,7979,486,1998,507,1168,638,9978,455,521
   > Total Current Assets 
1,684,074
1,850,094
1,726,711
2,046,525
1,893,037
1,811,738
1,853,102
2,093,617
1,533,102
1,538,807
1,595,689
1,625,239
1,669,462
1,682,816
1,746,116
0
0
0
0
16,509
55,169
106,175
111,381
125,349
87,623
85,890
73,647
76,149
63,782
59,098
92,206
85,119
76,006
65,997
57,645
49,545
46,342
43,871
39,144
31,925
50,374
43,840
38,218
35,744
52,368
46,407
121,730
113,727
103,117
93,355
87,041
81,086
119,447
114,431
107,669
102,992
102,992107,669114,431119,44781,08687,04193,355103,117113,727121,73046,40752,36835,74438,21843,84050,37431,92539,14443,87146,34249,54557,64565,99776,00685,11992,20659,09863,78276,14973,64785,89087,623125,349111,381106,17555,16916,50900001,746,1161,682,8161,669,4621,625,2391,595,6891,538,8071,533,1022,093,6171,853,1021,811,7381,893,0372,046,5251,726,7111,850,0941,684,074
       Cash And Cash Equivalents 
628,679
690,246
521,502
831,722
711,438
537,523
611,241
855,435
235,161
275,753
289,590
270,643
276,528
274,498
350,454
36,457
0
0
0
13,899
54,512
63,066
60,053
53,025
54,099
43,191
34,332
38,388
28,900
35,915
29,765
21,091
21,936
19,272
31,547
22,962
12,965
14,507
17,341
9,210
39,453
21,632
18,151
16,952
12,587
2,192
59,742
2,336
8,324
8,484
18,359
9,981
20,690
12,313
9,787
22,544
22,5449,78712,31320,6909,98118,3598,4848,3242,33659,7422,19212,58716,95218,15121,63239,4539,21017,34114,50712,96522,96231,54719,27221,93621,09129,76535,91528,90038,38834,33243,19154,09953,02560,05363,06654,51213,89900036,457350,454274,498276,528270,643289,590275,753235,161855,435611,241537,523711,438831,722521,502690,246628,679
       Short-term Investments 
13,231
16,195
15,470
23,079
23,809
27,576
24,697
26,559
28,420
27,697
9,680
5,726
16,084
15,881
17,798
0
0
0
0
1,954
0
39,891
48,750
42,510
31,949
40,735
36,198
33,759
33,034
21,306
60,616
64,028
52,164
45,057
24,414
26,583
30,054
27,891
20,723
21,934
10,376
19,802
17,995
14,737
38,050
41,869
56,612
105,575
90,342
80,070
59,015
56,165
93,695
96,268
92,344
75,622
75,62292,34496,26893,69556,16559,01580,07090,342105,57556,61241,86938,05014,73717,99519,80210,37621,93420,72327,89130,05426,58324,41445,05752,16464,02860,61621,30633,03433,75936,19840,73531,94942,51048,75039,89101,954000017,79815,88116,0845,7269,68027,69728,42026,55924,69727,57623,80923,07915,47016,19513,231
       Net Receivables 
541,463
578,419
681,116
678,403
641,472
685,933
651,588
677,077
749,396
723,547
752,047
802,650
803,290
784,680
764,618
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
630
0
0
0
0
831
245
2,039
89
90
129
435
426
426
873
11,775
1,625
1,287
2,087
2,436
2,4362,0871,2871,62511,77587342642643512990892,0392458310000630000000000000000000000764,618784,680803,290802,650752,047723,547749,396677,077651,588685,933641,472678,403681,116578,419541,463
       Inventory 
323,866
328,819
350,609
323,318
340,400
367,721
393,775
377,866
396,971
395,808
400,680
403,488
407,455
416,833
431,089
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-630
0
0
0
0
0
0
0
0
0
0
0
0
0
169
-2,950
-95,320
-96,268
-95,424
0
0-95,424-96,268-95,320-2,9501690000000000000-630000000000000000000000431,089416,833407,455403,488400,680395,808396,971377,866393,775367,721340,400323,318350,609328,819323,866
       Other Current Assets 
176,835
236,415
158,014
190,003
175,918
192,985
171,801
156,680
123,154
116,002
143,692
142,732
166,105
190,924
182,157
564
0
0
0
656
657
3,218
2,578
2,533
1,575
1,964
3,117
2,621
1,848
1,877
1,825
1,866
1,906
1,668
1,684
1,258
3,323
1,473
1,080
781
545
1,575
1,827
2,016
1,642
2,256
5,247
5,381
4,025
4,375
6,386
2,950
98,757
100,831
95,424
2,390
2,39095,424100,83198,7572,9506,3864,3754,0255,3815,2472,2561,6422,0161,8271,5755457811,0801,4733,3231,2581,6841,6681,9061,8661,8251,8771,8482,6213,1171,9641,5752,5332,5783,218657656000564182,157190,924166,105142,732143,692116,002123,154156,680171,801192,985175,918190,003158,014236,415176,835
   > Long-term Assets 
6,771,447
6,788,903
6,780,405
7,439,674
7,382,760
7,312,885
7,193,391
7,094,346
7,046,062
6,943,203
6,962,346
7,012,826
6,869,586
6,800,931
6,742,120
0
0
0
0
4,135
4,736
46,906
29,988
4,326
27,502
14,596
12,278
4,375
1,953
2,374
2,281
4,236
2,464
2,311
2,129
3,201
3,573
4,891
4,601
4,263
4,073
3,722
3,418
2,982
2,760
2,588
2,186
1,810
1,659
2,661
9,014
14,700
17,391
18,316
17,400
19,075
19,07517,40018,31617,39114,7009,0142,6611,6591,8102,1862,5882,7602,9823,4183,7224,0734,2634,6014,8913,5733,2012,1292,3112,4644,2362,2812,3741,9534,37512,27814,59627,5024,32629,98846,9064,7364,13500006,742,1206,800,9316,869,5867,012,8266,962,3466,943,2037,046,0627,094,3467,193,3917,312,8857,382,7607,439,6746,780,4056,788,9036,771,447
       Property Plant Equipment 
813,473
825,390
832,359
847,984
840,087
840,181
835,853
833,678
818,185
807,715
817,865
844,692
771,420
770,889
773,711
2,505
0
0
0
1,925
1,839
2,022
1,841
1,793
1,845
1,766
1,596
1,421
1,623
2,003
2,191
2,280
2,374
2,221
2,039
1,853
1,692
4,676
4,380
4,091
3,924
3,597
3,278
2,982
2,760
2,436
2,186
1,810
1,483
1,753
9,014
11,557
14,057
14,825
14,247
14,046
14,04614,24714,82514,05711,5579,0141,7531,4831,8102,1862,4362,7602,9823,2783,5973,9244,0914,3804,6761,6921,8532,0392,2212,3742,2802,1912,0031,6231,4211,5961,7661,8451,7931,8412,0221,8391,9250002,505773,711770,889771,420844,692817,865807,715818,185833,678835,853840,181840,087847,984832,359825,390813,473
       Goodwill 
3,794,702
3,833,415
3,869,638
4,372,073
4,393,841
4,408,410
4,380,537
4,366,584
4,406,761
4,394,660
4,444,257
4,503,392
4,497,298
4,494,768
4,500,208
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000004,500,2084,494,7684,497,2984,503,3924,444,2574,394,6604,406,7614,366,5844,380,5374,408,4104,393,8414,372,0733,869,6383,833,4153,794,702
       Long Term Investments 
42,326
23,158
24,519
22,448
22,368
26,650
25,855
24,996
24,162
28,179
27,560
26,677
29,266
28,892
28,465
0
0
0
0
29,814
0
0
0
29,814
25,557
12,655
10,329
4,002
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000004,00210,32912,65525,55729,81400029,814000028,46528,89229,26626,67727,56028,17924,16224,99625,85526,65022,36822,44824,51923,15842,326
       Intangible Assets 
2,008,710
1,969,597
1,906,637
2,040,175
1,966,396
1,890,469
1,812,298
1,746,701
1,679,830
1,606,359
1,555,745
1,525,823
1,461,585
1,388,275
1,321,174
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000001,321,1741,388,2751,461,5851,525,8231,555,7451,606,3591,679,8301,746,7011,812,2981,890,4691,966,3962,040,1751,906,6371,969,5972,008,710
       Long-term Assets Other 
98,014
119,301
125,974
130,242
134,907
121,442
114,800
93,582
91,422
83,425
93,621
89,234
90,346
97,890
98,057
0
0
0
0
2,210
2,897
146
137
-27,281
100
175
353
-1,048
330
371
90
1,956
90
90
90
1,348
1,881
215
221
172
149
125
140
213
234
152
158
158
176
175
-2,239
-22
144
72
-298
131
131-29872144-22-2,2391751761581581522342131401251491722212151,8811,3489090901,95690371330-1,048353175100-27,2811371462,8972,210000098,05797,89090,34689,23493,62183,42591,42293,582114,800121,442134,907130,242125,974119,30198,014
       Deferred Long Term Asset Charges 
14,222
18,042
21,278
26,752
25,161
25,733
24,048
28,805
25,702
22,865
23,298
23,008
19,671
20,217
20,505
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000020,50520,21719,67123,00823,29822,86525,70228,80524,04825,73325,16126,75221,27818,04214,222
> Total Liabilities 
4,273,802
4,243,195
3,939,698
5,048,170
4,890,422
4,571,353
4,470,095
4,588,737
3,875,566
3,790,164
3,943,534
3,984,602
3,852,727
3,663,395
3,511,460
12,703
0
0
0
15,716
157,911
13,740
12,212
14,625
14,693
13,917
11,936
17,723
15,029
21,441
22,199
25,110
23,972
22,932
20,788
19,096
20,430
18,536
17,009
15,162
12,480
11,624
9,638
7,242
5,596
8,190
6,477
6,411
6,402
9,558
19,049
24,502
27,140
26,695
26,866
31,597
31,59726,86626,69527,14024,50219,0499,5586,4026,4116,4778,1905,5967,2429,63811,62412,48015,16217,00918,53620,43019,09620,78822,93223,97225,11022,19921,44115,02917,72311,93613,91714,69314,62512,21213,740157,91115,71600012,7033,511,4603,663,3953,852,7273,984,6023,943,5343,790,1643,875,5664,588,7374,470,0954,571,3534,890,4225,048,1703,939,6984,243,1954,273,802
   > Total Current Liabilities 
1,120,412
1,478,047
1,132,692
1,146,385
1,788,981
1,479,112
1,404,444
1,496,306
1,082,056
1,014,975
1,121,668
1,192,351
1,071,116
934,243
801,304
5,207
0
0
0
9,794
11,545
9,372
8,776
12,849
13,191
13,917
11,936
8,525
6,549
9,649
9,720
10,391
11,022
11,084
10,723
10,833
11,175
11,304
11,828
12,923
10,445
9,799
8,033
5,864
4,451
7,284
5,820
6,013
6,269
9,260
11,213
13,862
13,654
12,368
12,881
16,416
16,41612,88112,36813,65413,86211,2139,2606,2696,0135,8207,2844,4515,8648,0339,79910,44512,92311,82811,30411,17510,83310,72311,08411,02210,3919,7209,6496,5498,52511,93613,91713,19112,8498,7769,37211,5459,7940005,207801,304934,2431,071,1161,192,3511,121,6681,014,9751,082,0561,496,3061,404,4441,479,1121,788,9811,146,3851,132,6921,478,0471,120,412
       Short-term Debt 
345,860
720,226
345,468
347,749
783,395
440,706
445,732
450,839
377,524
352,677
393,200
353,214
328,052
147,208
4,157
0
0
0
0
5,134
5,190
3,248
3,307
3,366
3,427
3,489
2,640
339
1,094
2,786
2,267
5,012
7,027
7,717
7,742
7,767
8,472
8,522
8,573
9,492
7,646
5,783
3,895
861
890
919
949
980
1,012
976
815
894
801
1,064
1,233
1,328
1,3281,2331,0648018948159761,0129809499198908613,8955,7837,6469,4928,5738,5228,4727,7677,7427,7177,0275,0122,2672,7861,0943392,6403,4893,4273,3663,3073,2485,1905,13400004,157147,208328,052353,214393,200352,677377,524450,839445,732440,706783,395347,749345,468720,226345,860
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,134
0
0
0
3,366
3,427
3,489
2,640
339
1,094
14,578
2,267
5,012
7,027
7,717
7,742
7,767
7,791
7,817
7,844
8,737
6,866
4,976
3,061
0
0
0
0
0
0
70
0
0
0
0
0
0
000000700000003,0614,9766,8668,7377,8447,8177,7917,7677,7427,7177,0275,0122,26714,5781,0943392,6403,4893,4273,3660005,1340000000000000000000
       Accounts payable 
651,593
648,134
675,440
679,329
629,246
664,464
566,879
649,294
588,819
555,817
610,130
707,841
613,206
653,138
678,998
1,055
0
0
0
1,433
3,168
3,002
1,590
3,872
5,876
4,723
3,565
2,606
1,246
2,669
3,592
2,276
1,462
832
599
1,040
834
664
1,324
847
748
603
1,352
1,431
1,161
2,224
900
1,031
1,563
1,674
3,129
3,106
3,965
516
2,043
3,529
3,5292,0435163,9653,1063,1291,6741,5631,0319002,2241,1611,4311,3526037488471,3246648341,0405998321,4622,2763,5922,6691,2462,6063,5654,7235,8763,8721,5903,0023,1681,4330001,055678,998653,138613,206707,841610,130555,817588,819649,294566,879664,464629,246679,329675,440648,134651,593
       Other Current Liabilities 
122,959
109,687
111,784
119,307
376,340
373,942
391,833
396,146
115,713
106,481
118,338
131,296
129,858
133,897
118,149
3,424
0
0
0
3,227
242
3,122
3,879
4,910
3,888
5,705
5,731
5,580
4,209
4,194
3,861
3,103
2,533
2,535
2,382
2,026
1,239
1,582
1,579
2,376
1,908
3,212
2,733
3,572
2,400
4,141
3,971
4,002
3,694
6,610
7,269
9,862
8,888
10,788
9,605
11,559
11,5599,60510,7888,8889,8627,2696,6103,6944,0023,9714,1412,4003,5722,7333,2121,9082,3761,5791,5821,2392,0262,3822,5352,5333,1033,8614,1944,2095,5805,7315,7053,8884,9103,8793,1222423,2270003,424118,149133,897129,858131,296118,338106,481115,713396,146391,833373,942376,340119,307111,784109,687122,959
   > Long-term Liabilities 
3,153,390
2,765,148
2,807,006
3,901,785
3,101,441
3,092,241
3,065,651
3,092,431
2,793,510
2,775,189
2,821,866
2,792,251
2,781,611
2,729,152
2,710,156
0
0
0
0
5,922
146,366
4,368
3,436
1,776
1,502
0
0
9,198
8,480
11,792
12,479
14,719
12,950
11,848
10,065
8,263
9,255
7,232
5,181
2,239
2,035
1,825
1,605
1,378
1,145
906
657
398
133
298
7,836
10,640
13,486
14,327
13,985
15,181
15,18113,98514,32713,48610,6407,8362981333986579061,1451,3781,6051,8252,0352,2395,1817,2329,2558,26310,06511,84812,95014,71912,47911,7928,4809,198001,5021,7763,4364,368146,3665,92200002,710,1562,729,1522,781,6112,792,2512,821,8662,775,1892,793,5103,092,4313,065,6513,092,2413,101,4413,901,7852,807,0062,765,1483,153,390
       Long term Debt Total 
2,289,660
1,921,397
1,925,709
2,727,624
2,298,841
2,298,473
2,298,072
2,297,653
2,047,308
2,047,280
2,061,280
2,060,855
2,068,979
2,068,224
2,067,587
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,263
6,440
4,600
2,742
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000002,7424,6006,4408,263000000000000000000002,067,5872,068,2242,068,9792,060,8552,061,2802,047,2802,047,3082,297,6532,298,0722,298,4732,298,8412,727,6241,925,7091,921,3972,289,660
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,496
3,337
3,168
2,994
2,815
2,632
2,439
2,239
2,035
1,825
1,606
1,378
1,145
1,204
8,651
11,534
14,287
15,391
15,218
15,095
15,09515,21815,39114,28711,5348,6511,2041,1451,3781,6061,8252,0352,2392,4392,6322,8152,9943,1683,3373,496000000000000000000000000000000000000
       Deferred Long Term Asset Charges 
14,222
18,042
21,278
26,752
25,161
25,733
24,048
28,805
25,702
22,865
23,298
23,008
19,671
20,217
20,505
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000020,50520,21719,67123,00823,29822,86525,70228,80524,04825,73325,16126,75221,27818,04214,222
       Long-term Liabilities Other 
344,931
343,077
357,059
616,179
324,688
342,976
244,328
293,573
291,724
285,386
297,844
316,026
294,925
237,924
239,206
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,815
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002,815000000000000000000000239,206237,924294,925316,026297,844285,386291,724293,573244,328342,976324,688616,179357,059343,077344,931
       Deferred Long Term Liability 
518,799
500,674
524,238
557,982
477,912
450,792
523,251
501,205
454,478
442,523
462,742
415,370
417,707
423,004
403,363
0
0
0
0
445
0
0
0
130
49
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000491300004450000403,363423,004417,707415,370462,742442,523454,478501,205523,251450,792477,912557,982524,238500,674518,799
> Total Stockholder Equity
4,181,719
4,373,147
4,559,418
4,434,076
4,381,262
4,549,320
4,572,957
4,599,226
4,703,598
4,691,428
4,614,336
4,652,681
4,685,624
4,819,873
4,976,561
24,669
0
0
0
4,928
-98,006
139,341
129,157
115,050
100,432
86,569
73,989
62,801
50,706
40,031
72,288
64,245
54,498
45,376
38,986
33,650
29,485
30,226
26,736
21,026
42,128
36,100
31,998
31,484
49,532
40,976
117,439
109,126
98,550
86,635
77,006
71,284
109,879
106,237
98,203
90,658
90,65898,203106,237109,87971,28477,00686,63598,550109,126117,43940,97649,53231,48431,99836,10042,12821,02626,73630,22629,48533,65038,98645,37654,49864,24572,28840,03150,70662,80173,98986,569100,432115,050129,157139,341-98,0064,92800024,6694,976,5614,819,8734,685,6244,652,6814,614,3364,691,4284,703,5984,599,2264,572,9574,549,3204,381,2624,434,0764,559,4184,373,1474,181,719
   Common Stock
1,983
1,995
2,024
2,072
2,086
2,101
2,109
2,117
2,155
2,164
2,173
2,187
2,212
2,227
2,229
1
0
0
0
10
1
24
24
24
24
24
24
24
24
24
30
30
30
30
30
31
37
49
50
4
9
9
10
11
16
16
28
28
28
28
29
29
53
57
59
63
635957532929282828281616111099450493731303030303024242424242424242411000012,2292,2272,2122,1872,1732,1642,1552,1172,1092,1012,0862,0722,0241,9951,983
   Retained Earnings Total Equity
245,710
356,278
461,818
532,499
626,186
721,652
817,923
910,991
1,043,630
1,165,984
1,231,840
1,341,846
1,463,042
1,589,682
1,707,928
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000000001,707,9281,589,6821,463,0421,341,8461,231,8401,165,9841,043,630910,991817,923721,652626,186532,499461,818356,278245,710
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
4,614,501
4,653,463
4,686,321
4,820,352
4,976,776
0
0
0
0
-2,963
-242
-106
-68
-171
-19
19
7
-76
-68
-57
-63
-120
-136
-85
-57
-60
-40
-32
-33
-40
-53
-44
-42
-43
-57
-61
-69
-263
-759
-810
-669
-433
-248
-333
-294
-74
-74-294-333-248-433-669-810-759-263-69-61-57-43-42-44-53-40-33-32-40-60-57-85-136-120-63-57-68-76719-19-171-68-106-242-2,96300004,976,7764,820,3524,686,3214,653,4634,614,5010000000000
   Capital Surplus 
4,854,640
4,912,578
4,995,986
5,222,859
5,287,557
5,376,521
5,413,813
5,441,061
5,590,410
5,631,103
5,670,084
5,731,568
5,819,030
5,876,790
5,897,194
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
332,378
334,324
340,893
343,048
343,524
362,723
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000362,723343,524343,048340,893334,324332,378000000000000000000005,897,1945,876,7905,819,0305,731,5685,670,0845,631,1035,590,4105,441,0615,413,8135,376,5215,287,5575,222,8594,995,9864,912,5784,854,640
   Treasury Stock00000000000000000000000000000000000000000-2,634,979-2,632,985-2,613,742-2,481,990-2,377,750-2,163,361-2,012,606-1,819,599-1,786,624-1,707,215-1,653,807-1,419,966-983,067-983,041-981,286
   Other Stockholders Equity 
60,672
85,337
82,657
96,612
119,240
156,261
125,736
64,656
80,009
55,538
87,989
59,070
15,082
-15,841
4,189
0
0
0
0
118,032
21,215
116,644
129,463
273,321
159,513
175,634
191,446
278,832
280,134
281,586
325,031
328,519
329,455
330,694
331,390
332,378
334,324
340,893
343,048
343,364
362,723
363,132
365,789
370,210
395,422
397,091
481,390
481,832
483,730
484,286
487,759
489,322
539,659
548,436
551,701
558,692
558,692551,701548,436539,659489,322487,759484,286483,730481,832481,390397,091395,422370,210365,789363,132362,723343,364343,048340,893334,324332,378331,390330,694329,455328,519325,031281,586280,134278,832191,446175,634159,513273,321129,463116,64421,215118,03200004,189-15,84115,08259,07087,98955,53880,00964,656125,736156,261119,24096,61282,65785,33760,672



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue353
Cost of Revenue-2,741
Gross Profit-2,388-2,388
 
Operating Income (+$)
Gross Profit-2,388
Operating Expense-52,531
Operating Income-54,919-54,919
 
Operating Expense (+$)
Research Development42,293
Selling General Administrative12,979
Selling And Marketing Expenses2,741
Operating Expense52,53158,013
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-54,919
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-50,397-59,441
EBIT - interestExpense = -54,919
-50,397
-50,389
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-54,919-50,397
Earnings Before Interest and Taxes (EBITDA)-52,178
 
After tax Income (+$)
Income Before Tax-50,397
Tax Provision-0
Net Income From Continuing Ops-43,159-50,397
Net Income-50,389
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses55,272
Total Other Income/Expenses Net4,5220
 

Technical Analysis of aTyr Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of aTyr Pharma Inc. The general trend of aTyr Pharma Inc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine aTyr Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of aTyr Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.06 < 2.11 < 2.1162.

The bearish price targets are: 1.55 > 1.48 > 1.48.

Tweet this
aTyr Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of aTyr Pharma Inc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

aTyr Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of aTyr Pharma Inc. The current macd is -0.06189706.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the aTyr Pharma Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for aTyr Pharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the aTyr Pharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
aTyr Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartaTyr Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of aTyr Pharma Inc. The current adx is 15.58.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell aTyr Pharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
aTyr Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of aTyr Pharma Inc. The current sar is 1.78663567.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
aTyr Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of aTyr Pharma Inc. The current rsi is 38.26. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
aTyr Pharma Inc Daily Relative Strength Index (RSI) ChartaTyr Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of aTyr Pharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the aTyr Pharma Inc price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
aTyr Pharma Inc Daily Stochastic Oscillator ChartaTyr Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of aTyr Pharma Inc. The current cci is -81.75519559.

aTyr Pharma Inc Daily Commodity Channel Index (CCI) ChartaTyr Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of aTyr Pharma Inc. The current cmo is -30.77227161.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
aTyr Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartaTyr Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of aTyr Pharma Inc. The current willr is -87.67123288.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
aTyr Pharma Inc Daily Williams %R ChartaTyr Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of aTyr Pharma Inc.

aTyr Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of aTyr Pharma Inc. The current atr is 0.10290435.

aTyr Pharma Inc Daily Average True Range (ATR) ChartaTyr Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of aTyr Pharma Inc. The current obv is 13,411,544.

aTyr Pharma Inc Daily On-Balance Volume (OBV) ChartaTyr Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of aTyr Pharma Inc. The current mfi is 31.06.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
aTyr Pharma Inc Daily Money Flow Index (MFI) ChartaTyr Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for aTyr Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

aTyr Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of aTyr Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.259
Ma 20Greater thanMa 501.770
Ma 50Greater thanMa 1001.824
Ma 100Greater thanMa 2001.643
OpenGreater thanClose1.680
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of aTyr Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on aTyr Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about aTyr Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about aTyr Pharma Inc

I send you an email if I find something interesting about aTyr Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about aTyr Pharma Inc.

Receive notifications about aTyr Pharma Inc in your mailbox!